Medite Cancer Diagnostics Inc · OTC:MDIT
Medite Cancer Diagnostics — Investor Presentation (December 2016)
56 slides from Medite Cancer Diagnostics's investor presentation, Dec 14, 2016
Slide 1: MEDITE Cancer Diagnostics, December 2016
MEDITE® ‘Cancer Diagnostics: December 2036
Slide 2: Confidential information and forward-looking statements
MEDITES = ‘CONFIDENTIAL INFORMATION. This information i published solely fr informational purposes and Ismot to be construed asa solicitation ran offer to buy any security oF elated fancialinstrument. ‘The summary may include forward-looking statements" wit the meaning of Section 27A of the Securiti
Slide 3: Full line manufacturer of Histo-Pathology and Cyto-Pathology
MEDITE =x Full line Manufacturer of Histo-Pathology and Cyto- Pathology instruments and consumables US corporation headquartered in Orlando, FL Publicly traded on OTCOB (Ticker:MDIT) Merged with US based CytoCore, Inc (Ticker: CYOE) in 2034, to gain MEDITE Cancer access to US public capital markets
Slide 4: Histo-Pathology
MEDITES == Histo-Pathology is the process of examining cells and tissues under a microscope which have been sectioned, stained and mounted on a slide Histo-Pathology generated approximately $8.0 milin 2035 revenue, forecast 2026 of $9.8mil to $10.2mil i TCA 44-720 (multistainer-glass-coverslipper co
Slide 5: SureThin specimen preparation system
MEDITES = SureThin® specimen preparation system (processing instrument, filters and preservatives) “Razor-razor blade” model drives recurring revenue Provides significant cost savings over competitor Acts as platform for SureCyte branded instant. staining products
Slide 6: Cyto-Pathology Future Products
MEDITE =x Cyto- Pathology Future Products Innovative SureCyte instant-staining method will support screening and diagnosis Eliminates human error and provides labor cost savings Stains within seconds vs, one+ hour for competitors products SureCyte chemical stains expected to enter market in China th
Slide 7: sift
MEDITES sift
Slide 8: Instruments, consumables, imagers and biomarkers in development
MEDITES Instruments, | INDEVELOPMENT: Consumables \ Biomarkers imagers > ‘Gyo: Pathology ~\~ Liquid Based ‘cjto-Pathology Consumables & Instruments
Slide 9: Customer Insights: Pain Points
MEDITE =x Customer Insights “Pain Points” Opportunities in Histo-Pathology and Cyto-Pathology exist Growth of evidence-based & personal Increasing demand for co, reflex and foll ized medicine won testing Highly complex and fragmented lab workflows Increasing test volumes world wide Increasing tumnar
Slide 10: Why MEDITE?
Why MEDITE? Only full-line manufacturer of Histo-Pathology and Cyto-Pathology products with a future global distribution footprint ‘Streamlined supply chain exbility, quick turnaround) instruments and supplies (20-508 less than comps nd sunply offerings reduce process sten Global installed use RED d
Slide 11: Product portfolio: SoftPAP/Softkit, SureCyte, SureThin
SoftPAP#/Softkit Self Collection-Tissue Specimen \ ia ie | Surecyte Stains Surecyte Assays ‘SureThin® Preservative SureThin® instrument r UNIC Imager LUNIC Workstation ~~. =
Slide 12: Global operations and facilities
MEDITE =x Orlando HO Corporate headquarters German Manufacturing Major production site Chicago R&D Molecular diagnostics MEDITE Automated cytology systems Operations China JV Major sales/distribution hub Digital pathology & telepathology systems Poland Manufacturing & R&D ‘On-going product developme
Slide 13: David Patterson - CEO
MEDITES == David Patterson ~ CEO (newly appointed in Nov 2036) + Healthcare Executive with over 30 years of progressive experience and achievernent of growth + Established contacts (resources) within industry leading payers, healthcare providers, and supplies of health care products and information
Slide 14: Richard Domanik PhD - Chief Scientist
MEDITES == ‘Richard Domanik PhD.- Chief Scientist (Formerly COO of CytoCore) + 35 years primanly as Chief Technology Officer for 4 companies including 2s years with ‘Abbott Laboratories and so with CytoCore and predecessor companies + Specialties include product definition, product engineering and d
Slide 15: Michael Jolley PhD - Senior Scientist
MEDITES == ‘Michael, Jolley, PhD. ~ Senior Scientist + 3B years asa Senior Scientist, Scientific Director ~ VP Research and Development, and President /Enteepeeneur incliding 36 years at Abbott Laboratories + Ideas and work behind success of several products generating billions in annual sales inclu
Slide 16: Worldwide Marketing & Sales Strategy
MEDITE =x Worldwide Marketing & Sales Strategy Protect installed base and obtain incremental market penetration Germany Direct sales and service departments with 4 sales reps and 4 service techs EU solely via distribution partners "extensive long term relationships with MEDITE China: SV w/ UNIC Medi
Slide 17: US/Americas: Market Strategy
MEDITE =x US/Americas: Market Strategy Increase US Sales of MEDITE Base Products ‘Three Group Purchasing Organizations provide access to s,000+ hospitals and labs Enhanced marketing/pricing programs to feature specific instrumentation and supplies (consumables) Provide an alternative to Hologic Thin
Slide 18: US/Americas: Sales & Distribution Channels
MEDITE =x US/Americas: Sales & Distribution Channels Established strategic distribution partnerships to drive Sales growth Signed contract with VWR, Inc. 40 Regional Sales Directors, 400 US based field reps, initially 56 reps committed to labs/healthcare MEDITE is one of 5 new primary product areas
Slide 19: =
MEDITES =
Slide 20: China: Sales & Distribution via UNIC Medical
MEDITE =x Direct sales via JV Partner, UNIC Medical based in Beijing, Shanghai and Suzhou UNIC Medical has an own team of 35 Regional Sales Reps and 180 independent field reps throughout China 5 trained service technicians for Histo-Pathology instrumentation China: UNIC building Sates Channel forthe
Slide 21: Molecular Diagnostics: Creating Value
MEDITE =x Molecular Diagnostics reating Value In Development” Patent Pending (2033) cancer risk assay biomarkers currently in development Total Global Potential Addressable Market = ~$2 Billion Completed CytoCore integration in early 2026 Risk assessment for multiple types of cancer (e.g. lung, blad
Slide 22: Capitalize on Opportunity: Operational Improvements
MEDITE =x Capitalize on Opportunity to Build on Installed Base: Operational Improvements Operational improvements Leverage existing installed base of instruments to drive sales of higher margin consumables Realize efficiencies from these higher sales volumes Develop an internal sales and service tea
Slide 23: Capitalize on Opportunity: Incremental Value Creation
MEDITE =x Capitalize on Opportunity to Build on Installed Base: Incremental Value Creation Incremental Value Creation Create a US based marketing/product development team to support both existing and new products Gain SureThin® FDA clearance for the LBC GYN market Introduce consumer health specimen
Slide 24: !
MEDITE!
Slide 25: (soon
MEDITES == (soon Pres. sont Vee name mF Pers Heroines ane son "ake Trl Puta Sale + tte thr sonar rocenmates sown sige 8 sat ‘crower vom aoe Tol Gre Peto Sales + aa Sos ae ncl ‘ou sis © anys Prey z S Geass rote a eT ec cote ar ae ed eo rr re me ed NecicomeaterNOLGnyforwed 6 Gu) + Mele SK a nd Ch
Slide 26: Private Placement offering summary
MEDITES = esr: [MEDITE Cancer Diagnostics In. Industry Medial Equipment & Diagnostics Ticker (oTc08. Mort Type of Offering: Private Placement ‘Securities Ofered Common Stock Unit Offering Price: sosopershare Valuation +1084 millon Pre Money Expected Closing Decemberas 2016 lesver' Counsel ‘ONeal Law
Slide 27: MEDITE Cancer Diagnostics capitalization
MEDITES =x MEDITE Cancer Diagnostics, Inc. (OTCaB: MDIT) As of og/09/16 Market Shares Outstanding (Fully Diluted) 22,674,758 Capitalization . Market Price $0.55 Market Value $11.92 million Confidential information - Not for Public Dissemination octos: Morr
Slide 28: TriPoint Global Equities
TRIPOINT GLOBAL EQUITIES, LLC Robert Nathan | Director rnathan@tpglobal.com +1 (937) 450-3872 1450 Broadway, 26" Floor New York, NY 10028
Slide 29: MEDITE Cancer Diagnostics, December 2016
MEDITE® ‘Cancer Diagnostics: December 2036
Slide 30: Confidential information and forward-looking statements
MEDITES = ‘CONFIDENTIAL INFORMATION. This information i published solely fr informational purposes and Ismot to be construed asa solicitation ran offer to buy any security oF elated fancialinstrument. ‘The summary may include forward-looking statements" wit the meaning of Section 27A of the Securiti
Slide 31: Full line manufacturer of Histo-Pathology and Cyto-Pathology
MEDITE =x Full line Manufacturer of Histo-Pathology and Cyto- Pathology instruments and consumables US corporation headquartered in Orlando, FL Publicly traded on OTCOB (Ticker:MDIT) Merged with US based CytoCore, Inc (Ticker: CYOE) in 2034, to gain MEDITE Cancer access to US public capital markets
Slide 32: Histo-Pathology
MEDITES == Histo-Pathology is the process of examining cells and tissues under a microscope which have been sectioned, stained and mounted on a slide Histo-Pathology generated approximately $8.0 milin 2035 revenue, forecast 2026 of $9.8mil to $10.2mil i TCA 44-720 (multistainer-glass-coverslipper co
Slide 33: SureThin specimen preparation system
MEDITES = SureThin® specimen preparation system (processing instrument, filters and preservatives) “Razor-razor blade” model drives recurring revenue Provides significant cost savings over competitor Acts as platform for SureCyte branded instant. staining products
Slide 34: Cyto-Pathology Future Products
MEDITE =x Cyto- Pathology Future Products Innovative SureCyte instant-staining method will support screening and diagnosis Eliminates human error and provides labor cost savings Stains within seconds vs, one+ hour for competitors products SureCyte chemical stains expected to enter market in China th
Slide 35: sift
MEDITES sift
Slide 36: Instruments, consumables, imagers and biomarkers in development
MEDITES Instruments, | INDEVELOPMENT: Consumables \ Biomarkers imagers > ‘Gyo: Pathology ~\~ Liquid Based ‘cjto-Pathology Consumables & Instruments
Slide 37: Customer Insights: Pain Points
MEDITE =x Customer Insights “Pain Points” Opportunities in Histo-Pathology and Cyto-Pathology exist Growth of evidence-based & personal Increasing demand for co, reflex and foll ized medicine won testing Highly complex and fragmented lab workflows Increasing test volumes world wide Increasing tumnar
Slide 38: Why MEDITE?
Why MEDITE? Only full-line manufacturer of Histo-Pathology and Cyto-Pathology products with a future global distribution footprint ‘Streamlined supply chain exbility, quick turnaround) instruments and supplies (20-508 less than comps nd sunply offerings reduce process sten Global installed use RED d
Slide 39: Product portfolio: SoftPAP/Softkit, SureCyte, SureThin
SoftPAP#/Softkit Self Collection-Tissue Specimen \ ia ie | Surecyte Stains Surecyte Assays ‘SureThin® Preservative SureThin® instrument r UNIC Imager LUNIC Workstation ~~. =
Slide 40: Global operations and facilities
MEDITE =x Orlando HO Corporate headquarters German Manufacturing Major production site Chicago R&D Molecular diagnostics MEDITE Automated cytology systems Operations China JV Major sales/distribution hub Digital pathology & telepathology systems Poland Manufacturing & R&D ‘On-going product developme
Slide 41: David Patterson - CEO
MEDITES == David Patterson ~ CEO (newly appointed in Nov 2036) + Healthcare Executive with over 30 years of progressive experience and achievernent of growth + Established contacts (resources) within industry leading payers, healthcare providers, and supplies of health care products and information
Slide 42: Richard Domanik PhD - Chief Scientist
MEDITES == ‘Richard Domanik PhD.- Chief Scientist (Formerly COO of CytoCore) + 35 years primanly as Chief Technology Officer for 4 companies including 2s years with ‘Abbott Laboratories and so with CytoCore and predecessor companies + Specialties include product definition, product engineering and d
Slide 43: Michael Jolley PhD - Senior Scientist
MEDITES == ‘Michael, Jolley, PhD. ~ Senior Scientist + 3B years asa Senior Scientist, Scientific Director ~ VP Research and Development, and President /Enteepeeneur incliding 36 years at Abbott Laboratories + Ideas and work behind success of several products generating billions in annual sales inclu
Slide 44: Worldwide Marketing & Sales Strategy
MEDITE =x Protect installed base and obtain incremental market penetration Germany Direct sales and service departments with 4 sales reps and 4 service techs EU solely via distribution partners "extensive long term relationships with MEDITE : CChina: V w/ UNIC Medical based out of Shanghai, Beijing
Slide 45: US/Americas: Market Strategy
MEDITE =x US/Americas: Market Strategy Increase US Sales of MEDITE Base Products ‘Three Group Purchasing Organizations provide access to s,000+ hospitals and labs Enhanced marketing/pricing programs to feature specific instrumentation and supplies (consumables) Provide an alternative to Hologic Thin
Slide 46: US/Americas: Sales & Distribution Channels
MEDITE =x US/Americas: Sales & Distribution Channels Established strategic distribution partnerships to drive Sales growth Signed contract with VWR, Inc. 40 Regional Sales Directors, 400 US based field reps, initially 56 reps committed to labs/healthcare MEDITE is one of 5 new primary product areas
Slide 47: =
MEDITES =
Slide 48: China: Sales & Distribution via UNIC Medical
MEDITE =x Direct sales via JV Partner, UNIC Medical based in Beijing, Shanghai and Suzhou UNIC Medical has an own team of 35 Regional Sales Reps and 180 independent field reps throughout China 5 trained service technicians for Histo-Pathology instrumentation China: UNIC building Sates Channel forthe
Slide 49: Molecular Diagnostics: Creating Value
MEDITE =x Molecular Diagnostics reating Value In Development” Patent Pending (2033) cancer risk assay biomarkers currently in development Total Global Potential Addressable Market = ~$2 Billion Completed CytoCore integration in early 2026 Risk assessment for multiple types of cancer (e.g. lung, blad
Slide 50: Capitalize on Opportunity: Operational Improvements
MEDITE =x Capitalize on Opportunity to Build on Installed Base: Operational Improvements Operational improvements Leverage existing installed base of instruments to drive sales of higher margin consumables Realize efficiencies from these higher sales volumes Develop an internal sales and service tea
Slide 51: Capitalize on Opportunity: Incremental Value Creation
MEDITE =x Capitalize on Opportunity to Build on Installed Base: Incremental Value Creation Incremental Value Creation Create a US based marketing/product development team to support both existing and new products Gain SureThin® FDA clearance for the LBC GYN market Introduce consumer health specimen
Slide 52: !
MEDITE!
Slide 53: (soon
MEDITES == (soon Pres. sont Vee name mF Pers Heroines ane son "ake Trl Puta Sale + tte thr sonar rocenmates sown sige 8 sat ‘crower vom aoe Tol Gre Peto Sales + aa Sos ae ncl ‘ou sis © anys Prey z S Geass rote a eT ec cote ar ae ed eo rr re me ed NecicomeaterNOLGnyforwed 6 Gu) + Mele SK a nd Ch
Slide 54: Private Placement offering summary
MEDITES = esr: [MEDITE Cancer Diagnostics In. Industry Medial Equipment & Diagnostics Ticker (oTc08. Mort Type of Offering: Private Placement ‘Securities Ofered Common Stock Unit Offering Price: sosopershare Valuation +1084 millon Pre Money Expected Closing Decemberas 2016 lesver' Counsel ‘ONeal Law
Slide 55: MEDITE Cancer Diagnostics capitalization
MEDITES =x MEDITE Cancer Diagnostics, Inc. (OTCaB: MDIT) As of og/09/16 Market Shares Outstanding (Fully Diluted) 22,674,758 Capitalization . Market Price $0.55 Market Value $11.92 million Confidential information - Not for Public Dissemination octos: mor
Slide 56: TriPoint Global Equities
TRIPOINT GLOBAL EQUITIES, LLC Robert Nathan | Director rnathan@tpglobal.com +1 (937) 450-3872 1450 Broadway, 26" Floor New York, NY 10028
MEDITE Cancer Diagnostics — Investor Presentation (December 2016) on 6ix